These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 32234169)
21. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes. Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439 [TBL] [Abstract][Full Text] [Related]
22. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia. Bains A; Luthra R; Medeiros LJ; Zuo Z Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125 [TBL] [Abstract][Full Text] [Related]
23. [Genomic aberrations in myelodysplastic syndromes and related disorders]. Makishima H Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151 [TBL] [Abstract][Full Text] [Related]
24. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333 [TBL] [Abstract][Full Text] [Related]
25. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Zhang Y; Zhang M; Yang L; Xiao Z Leuk Res; 2007 Jan; 31(1):109-11. PubMed ID: 16678898 [TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631 [TBL] [Abstract][Full Text] [Related]
27. [Clinical implications and prognostic value of TP53 gene mutation and deletion in patients with myelodysplastic syndromes]. Huang HJ; Shi ZX; Li B; Qin TJ; Xu ZF; Zhang HL; Fang LW; Hu NB; Pan LJ; Qu SQ; Liu D; Cai YN; Zhang YD; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):215-221. PubMed ID: 30929389 [No Abstract] [Full Text] [Related]
29. Mutations of myelodysplastic syndromes (MDS): An update. Ganguly BB; Kadam NN Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316 [TBL] [Abstract][Full Text] [Related]
30. [Characteristics and Clinical Significance of Gene Mutation in Patients with Myelodysplastic Syndrome]. Zhao F; Wang KL; Qin YT; Nilupar T; Patiguli A; Jiang M; Hao JP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1864-1868. PubMed ID: 34893124 [TBL] [Abstract][Full Text] [Related]
31. [Analysis of RUNX1 Gene Mutation in Patients with Myelodysplastic Syndrome]. Cai XH; Chen MY; Chao HY; Jiang NK; Lu XZ; Han WM; Qin W; Jia ZX Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):202-208. PubMed ID: 32027277 [TBL] [Abstract][Full Text] [Related]
32. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885 [TBL] [Abstract][Full Text] [Related]
33. Update on cytogenetic and molecular changes in myelodysplastic syndromes. Schlegelberger B; Göhring G; Thol F; Heuser M Leuk Lymphoma; 2012 Apr; 53(4):525-36. PubMed ID: 21877899 [TBL] [Abstract][Full Text] [Related]
34. Distinct mutation features and its clinical significance in myelodysplastic syndromes with normal karyotype. Huang N; Chang C; Wu L; He Q; Zhang Z; Li X; Xu F Ann Hematol; 2024 Nov; 103(11):4485-4495. PubMed ID: 39302466 [TBL] [Abstract][Full Text] [Related]
35. Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes. Xu F; Wu LY; He Q; Wu D; Zhang Z; Song LX; Zhao YS; Su JY; Zhou LY; Guo J; Chang CK; Li X Sci Rep; 2017 Feb; 7():43113. PubMed ID: 28220884 [TBL] [Abstract][Full Text] [Related]
37. Constitutional mutations of the CHEK2 gene are a risk factor for MDS, but not for de novo AML. Janiszewska H; Bąk A; Skonieczka K; Jaśkowiec A; Kiełbiński M; Jachalska A; Czyżewska M; Jaźwiec B; Kuliszkiewicz-Janus M; Czyż J; Kuliczkowski K; Haus O Leuk Res; 2018 Jul; 70():74-78. PubMed ID: 29902706 [TBL] [Abstract][Full Text] [Related]
38. Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype. Tariq H; Barnea Slonim L; Coty Fattal Z; Alikhan MB; Segal J; Gurbuxani S; Helenowski IB; Zhang H; Sukhanova M; Lu X; Altman JK; Chen QC; Behdad A Br J Haematol; 2022 Jun; 197(6):736-744. PubMed ID: 35304738 [TBL] [Abstract][Full Text] [Related]
39. Somatic Mutations and the Risk of Undifferentiated Autoinflammatory Disease in MDS: An Under-Recognized but Prognostically Important Complication. Watad A; Kacar M; Bragazzi NL; Zhou Q; Jassam M; Taylor J; Roman E; Smith A; Jones RA; Amital H; Cargo C; McGonagle D; Savic S Front Immunol; 2021; 12():610019. PubMed ID: 33679746 [No Abstract] [Full Text] [Related]
40. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]